592508-72-0

Upstream product

• 35094-91-8 4-(p-tolyloxy)phenol 
• 106-95-6 allyl bromide 
• 61343-83-7 4-(4-methylphenoxy)benzaldehyde 
• 459-57-4 4-fluorobenzaldehyde 
• 106-44-5 p-cresol 

Downstream Products

• 656233-18-0 2-imino-5-{4-[3-(2-propyl-4-p-tolyloxy-phenoxy)-propoxy]-phenyl}-thiazolidin-4-one 
• 592508-47-9 hydroxy-{4-[3-(2-propyl-4-p-tolyloxy-phenoxy)-propoxy]-phenyl}-acetic acid methyl ester 
• 228578-10-7 2-Propyl-4-(4'-methylphenoxy)phenol 
• 228579-11-1 4-(4'-methylphenoxy)-2-allylphenol 

Relevant academic research and scientific papers

ARYLTHIAZOLIDINEDIONE DERIVATIVES

Substituted 5-aryl-2,4-thiazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR alpha , delta and/or gamma mediated diseases, disorders and conditions.

5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists

A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.

Arylthiazolidinedione and aryloxazolidinedione derivatives

Substituted 5-aryl-2,4-thiazolidinediones or 5-aryl-2,4-oxazolidinediones that also carry a second substituent in the 5-position of the heterocyclic ring are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR α, δ and/or γ mediated diseases, disorders and conditions.

Arylthiazolidinedione derivatives

Substituted 5-aryl-2,4-thiazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR α, δ and/or γ mediated diseases, disorders and conditions.